🔎 Trials Near Me

Beranda › Kanker Darah › Wisconsin › Milwaukee

Uji klinis Kanker Darah di Milwaukee, WI

12 studi untuk Kanker Darah mencari peserta di lokasi sekitar Milwaukee (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Aurora Cancer Care-Milwaukee, Milwaukee
  • Aurora Saint Luke's Medical Center, Milwaukee
  • Aurora Sinai Medical Center, Milwaukee
  • dan 9 lainnya
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Menerima pesertaStudi observasional
  • Children's Hospital of Wisconsin, Milwaukee
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Menerima pesertaFase 3
  • Medical College of Wisconsin, Milwaukee
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Menerima pesertaStudi observasional
  • Aurora Cancer Care-Milwaukee, Milwaukee
  • Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
  • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
  • dan 14 lainnya
Semua usia · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04242095

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Menerima pesertaFase 3
  • Froedtert & Medical College of Wisconsin, Milwaukee
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Froedtert & Medical College Clinics, Milwaukee
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

Menerima pesertaStudi observasional
  • Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT04892823

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Children's Hospital of Wisconsin, Milwaukee
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Menerima pesertaStudi observasional
  • Children's Hospital of Wisconsin., Milwaukee
Hingga usia 30 · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT06579469

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Menerima pesertaFase 1
  • Medical College of Wisconsin Cancer Center, Milwaukee
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184

CIBMTR Research Database

Menerima pesertaStudi observasional
  • Medical College of Wisconsin, Milwaukee
Semua usia · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT01166009

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Menerima pesertaFase 1
  • Children's Hospital of Wisconsin, Milwaukee
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Uji klinis Kanker Darah di kota lain

Studi lain di Milwaukee

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.